MedTrace Logo

Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China

NCT05682599 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2023-01-31

No results posted yet for this study

Summary

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 in China

Conditions

Interventions

DRUG

Azvudine

Azvudine is a novel nucleoside reverse transcriptase inhibitor.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

    collaborator INDUSTRY

  • Henan Genuine Biotech Co., Ltd.

    collaborator INDUSTRY

  • Shanghai Henlius Biotech

    lead INDUSTRY

Principal Investigators

  • chen mingquan · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-06
Primary Completion
2023-04-15
Completion
2023-05-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05682599 on ClinicalTrials.gov